Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0

作者：

Toffart, A. -C. ^{[1
,2
]}

Sakhri, L. ^{[1
,2
]}

Moro-Sibilot, D. ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France

[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期

关键词：

EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;

D O I：

10.1016/j.pneumo.2012.11.010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：111 / 116

页数：6

共 50 条

[21] Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non-Small Cell Lung Cancer?
Crystal, Adam S.
Shaw, Alice T.
CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4479 - 4481
[22] Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Gandhi, Leena
Jaenne, Pasi A.
CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3737 - 3742
[23] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
Won, Brian
Mambetsariev, Isa
Salgia, Ravi
BMC CANCER, 2016, 16
[24] Finding a place for ceritinib in the landscape of ALK-positive non-small cell lung cancer
Shum, Elaine
Gandhi, Leena
TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S215 - S218
[25] Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
Xu, Haiyan
Ma, Di
Yang, Guangjian
Li, Junling
Hao, Xuezhi
Xing, Puyuan
Yang, Lu
Xu, Fei
Wang, Yan
CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (02) : 349 - 356
[26] ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
McLeer-Florin, Anne
Duruisseaux, Michael
Pinsolle, Julian
Dubourd, Sylvian
Mondet, Julie
Houlbracq, Mathilde Phillips
Magnat, Nelly
Faure, Julien
Chatagnon, Amandine
de Fraipont, Florence
Levra, Matteo Giaj
Toffart, Anne-Claire
Ferretti, Gilbert
Hainaut, Pierre
Brarribilla, Elisabeth
Moro-Sibilot, Denis
Lantuejoul, Sylvie
LUNG CANCER, 2018, 116 : 15 - 24
[27] Role of STK11 in ALK-positive non-small cell lung cancer
Zhou, Wen
Yan, Lu-Da
Yu, Zhi-Qiong
Li, Na
Yang, Yong-Hua
Wang, Meng
Chen, Yuan-Yuan
Mao, Meng-Xia
Peng, Xiao-Chun
Cai, Jun
ONCOLOGY LETTERS, 2022, 23 (06)
[28] Alectinib for advanced ALK-positive non-small-cell lung cancer
Ly, Ashley C.
Olin, Jacqueline L.
Smith, Morgan B.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
[29] Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Yoshida, Tatsuya
Oya, Yuko
Tanaka, Kosuke
Shimizu, Junichi
Horio, Yoshitsugu
Kuroda, Hiroaki
Sakao, Yukinori
Hida, Toyoaki
Yatabe, Yasushi
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3383 - +
[30] Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema
Van Damme, Eufra
Kiselinova, Maja
Van Schoote, Elke
TUMORI JOURNAL, 2019, 105 (06): : NP35 - NP37

← 1 2 3 4 5 →